Compare Funko Inc (FNKO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs BIO-TECHNE Corp — how do they compare? Funko Inc trades at $6.49 (market cap $353.05M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 32.2× Funko Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Funko Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and BIO-TECHNE Corp for 63 Days on average.
| FNKO | TECH | |
|---|---|---|
Market Cap | $353.05M | $11.37B |
Volume | 915,655 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $72.61 |
52-Week Low | $2.81 | $43.31 |
Typical Hold Time | 33 Days | 63 Days |
Enterprise Value | $573.70M | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.50, up 6.38% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with Q2 2026 earnings beating expectations, revenue growth of 7% to $207.7M, and raised EBITDA guidance to $105M. Despite negative net margins, the stock trades at attractive valuations with P/S of 0.37 and EV/EBITDA of 6.7x. Recent management changes and product expansions signal strategic repositioning.
FNKO presents a turnaround opportunity with improving operational metrics and analyst consensus target of $7.58 (17% upside). Key risks include persistent negative profitability, high debt levels, and consumer discretionary sensitivity. The bullish technical setup combined with fundamental improvements supports cautious optimism for value investors seeking exposure to pop culture branding.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
